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Abstract
Background: Evidences have identified the correlation of 8-oxoguanine DNA glycosylase-1 (OGG1) and eph-
receptor tyrosine kinase-type A2 (EPHA2) polymorphisms in age-related cataract (ARC) risk. However, the results
were not consistent. The objective of this study was to examine the role of these two gene polymorphisms in ARC
susceptibility.
Methods: Eligible case–control studies published between January 2000 and 2015 were searched and retrieved in
the electronic databases. The odds ratio with 95 % confidence interval (CI) was employed to calculate the strength
of the relationship.
Results: We totally screened out six articles, including 5971 cataract patients and 4189 matched controls. Three
variants were contained (OGG1 rs1052133; EPHA2 rs7543472 and rs11260867). For OGG1 rs1052133, we detected a
significant correlation between OGG1 polymorphism and ARC risk under the heterogenous model (CG vs. CC:
OR = 1.34, 95 % CI = 1.06–1.70, P = 0.01) and dominant model (GG+CG vs. CC: OR = 1.45, 95 % CI = 1.16–1.81, P = 0.
001), especially in patients with cortical cataract of subgroup analysis by phenotypes (P < 0.05). For EPHA2
rs7543472 and rs11260867, we did not find a positive association between these two mutations and ARC
susceptibility in total cases. Subgroup analysis by phenotypes of cataract showed that only in cortical cataract,
genotypes of rs7543472 under the allele model, homogenous model and recessive model; genotypes of
rs11260867 under the heterogenous model and dominant model were associated with ARC risk.
Conclusions: OGG1 rs1052133 (CG and CG+GG genotypes) might be risk factor for ARC, particularly in cortical
cataract risk. EPHA2 rs7543472 (T allele and TT genotype) and rs11260867 (CG and GG+CG genotypes) might be
associated with cortical cataract.
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Background
Cataract is a leading cause of blindness and visual
impairment throughout the world, increasing the pub-
lic health and economic burden of this disease [1].
According to the Global estimates of visual impair-
ment, approximate 51 % of blindness and 33 % of
visual impairment were estimated due to cataract be-
tween 2000 and 2010 [2]. In addition, there are ra-
cial/ethnic disparities in the prevalence of cataract [3]:
Cataract of Europeans accounts for 50 % (WHO cri-
teria) to 65 % (US criteria) of unilateral visual impair-
ment, and 45 % (US criteria) of 5-year incident
bilateral visual impairment [4]; Asian populations had
a higher prevalence and earlier age of onset of cata-
ract than Europeans [5]; while the prevalence of cata-
ract was lower in Africans compared with Europeans
[6]. The major risk factors for cataract are age, as
well as several demographic and lifestyle characteris-
tics [7, 8]. Approximately 80 % of cataract is age-
related cataract (ARC) [9]. Based on the location of
the opacity in the lens, ARC is classified as cortical
cataract, nuclear cataract, or posterior subcapsular
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cataract [10]. The prevalence of ARC is rising, with a
prediction that 30.1 million Americans will be af-
fected by 2020 [11]. However, its etiology is multi-
factorial and not fully understood to date.
Etiological research have found that the set of genes
were associated with cataract, especially for ARC [12]. In
recent years, 8-oxoguanine DNA glycosylase-1 (OGG1)
and eph-receptor tyrosine kinase-type A2 (EPHA2) have
been identified as key regulators in lens clarity. OGG1 is
located in human chromosome 3p26.2, and its protein is
a key enzyme in base excision repair (BER) pathway
[13]. It is involved in maintaining genome integrity and
preventing cancer development [14]. OGG1 could be
used as a therapeutic target for certain types of cancer in
monotherapy or combination therapy [15]. OGG1 is also
implicated in oxidative mechanisms which play an im-
portant role in the pathogenesis of ARC, and might in-
crease the risk of developing ARC [16]. Single nucleotide
polymorphism (SNP) of OGG1 was shown to be a risk
factor for oxidative pathologies. The most studied vari-
ant was OGG1 gene rs1052133 (Ser326Cys), a C to G
transversion at nucleotide 1245, leading to a serine to
cysteine substitution at residue 326 located in the C-
terminal domain of the protein. The Cys326 protein has
been shown to have about 7 times weaker 8-
hydroxyguanine-repair capacity than Ser326 protein
[17]. Homozygous carriers of the S326C OGG1 poly-
morphism presented reduced repair activity, and C326
OGG1 homozygous carriers might be at increased risk
of oxidative pathologies [18].
EPHA2, located in human chromosome 1p36, is a
member of the Eph receptor tyrosine kinases family
[19]. It is an important regulator of tumor initiation,
neo-vascularization and metastasis in a wide range of
epithelial and mesenchymal cancers [20, 21]. EPHA2
is highly expressed in aggressive human cancers, and
also offers opportunities for Eph/ephrin-based tar-
geted drug delivery and imaging [22, 23]. EPHA2 pro-
tein is expressed in human and mouse lens [24, 25].
Multiple mutations in the EPHA2 gene have been re-
cently shown to cause cataracts in humans, contribut-
ing to the destabilization of the receptor and the loss
of cell migration activity [26]. The TT genotype of
rs7543472 was shown to be associated with ~2× in-
creased risk for cataracts; rs3754334 might be a vari-
ant on the EPHA2 gene that is commonly associated
with the risk for ARC in different ethnical and geo-
graphical populations [27].
Although epidemiologic studies have identified the
correlation of these genes polymorphisms in ARC risk,
however, the results remain inconclusive. Therefore, we
conducted this meta-analysis to establish the true associ-
ation between OGG1 and EPHA2 SNPs and the risk for
ARC.
Methods
Identification of eligible articles
We performed a comprehensive literature search in the
following electronic databases of Medline, PubMed,
Springer and Elsevier to retrieve relevant articles pub-
lished between January 2000 and 2015. The key terms
were “cataract” or “age-related cataract”, “8-oxoguanine
glycosylase-1 or OGG1 or DNA repair gene”, “Eph-re-
ceptor tyrosinekinase-type A2 or EPHA2”, and “variant
or polymorphism” as well as their combinations. Refer-
ences of related studies were manually searched to ob-
tain more sources. Only studies written in English were
included in this meta-analysis.
Criteria for inclusion and exclusion
The inclusion criteria were as follows: 1) case–control
studies concerning the role of OGG1 or EPHA2 poly-
morphisms in ARC risk; 2) patients with ARC was de-
fined as lens opacity along with disturbance of vision
and were over 50 years old (cataract status was deter-
mined by lens examination using a slit-lamp biomicro-
scope; lens opacities were determined using the Lens
Opacities Classification System III [28]); controls were
age-, sex-, and ethnically matched individuals without
history of cataract, hypertension, or other ocular dis-
eases; 3) the genotype information were available to ex-
tract, and the results were expressed as odds ratio (OR)
with 95 % confidence interval (CI); 4) when the same au-
thors or laboratories reported the issue among the same
populations in more articles, only the recent full-text ar-
ticles were included; and 5) genotype distribution of
control for a certain polymorphism must be in Hardy-
Weinberg equilibrium (HWE).
The exclusion criteria were: 1) review reports or con-
ference papers; 2) without control group; 3) studies with
duplicate data; and 4) genotype information couldn’t be
extracted.
Quality assessment and data extraction
Two investigators independently assessed the quality of
related articles. Any disagreement was subsequently re-
solved by discussion with another expert to reach a con-
sensus on all of the items. The following information
was extracted from each article: first author, year of pub-
lication, country, ethnicity, mean age, sample size, geno-
typing method, and genotype distribution in cases and
controls.
Statistical analysis
The strength of association between polymorphisms of
OGG1, EPHA2 and ARC risk was measured by the pooled
ORs with its 95 % CI. The Z test was employed to deter-
mine the significance of the pooled ORs, and a P value less
than 0.05 was considered statistically significant. For all
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the genetic polymorphisms, the comparison models (al-
lelic model; homogenous model; heterogenous model;
dominant model; and recessive model) were examined.
The I2 test and the Q-statistic test were used to estimate
between-study heterogeneity. The random-effect model
was employed when the P-value less than 0.10 for the
Q-test and I2 more than 50 %; otherwise, the fixed-effects
model was used. The evidence of publication bias was
assessed by visual funnel plot inspection. Statistical ana-
lyses were conducted in Review Manager (RevMan
version 5.3, the Cochrane Collaboration, Oxford,
England). All the tests were two-sided.
Results
Literature search and meta-analysis databases
We finally screened out 6 relevant articles, including
5971 cataract patients and 4189 controls. Figure 1 pre-
sented the flow diagram of searching process. The six
studies were conducted in five countries (USA [29],
India [30], China [31, 32], Sweden [33], Egypt [34]) and
contained three SNPs (one for OGG1: rs1052133; two
for EPHA2: rs7543472 and rs11260867). All these arti-
cles were written in English, and genetic polymorphisms
of OGG1 and EPHA2 were measured by polymerase
chain reaction. The genotype distribution in controls
were all in accord with HWE (P > 0.05). Tables 1 and 2
listed the essential information of included studies in
this meta-analysis. Figure 2 presented the distribution of
genotype information.
Association between OGG1 rs1052133 (C/G) and ARC risk
Table 3 showed the results of test for relationship
between OGG1 and EPHA2 polymorphisms and ARC
risk based on different genetic models in total and
subgroup analysis.
Three articles concerned the OGG1 variant, includ-
ing 1069 patients and 680 controls. Although the fre-
quency of G allele (minor) was shown to be higher in
ARC cases than that in controls (45.4 versus 35.5 %),
our result found that the G allele was not associated
with ARC susceptibility in the random-effect model
(OR = 1.36, 95 % CI = 0.99–1.87, P = 0.05). This insig-
nificance was also found under the homogenous
model and recessive model (P > 0.05). But we detected
a significant correlation between OGG1 polymorph-
ism and ARC risk in the heterogenous model (CG vs.
CC: OR = 1.34, 95 % CI = 1.06–1.70, P = 0.01) and
dominant model (GG+CG vs. CC: OR = 1.45, 95 % CI
= 1.16–1.81, P = 0.001) in the fixed-effect model as
shown in Fig. 2. Subgroup analysis by phenotypes of
cataract showed that only in cortical, not nuclear or
posterior subcapsular cataract, OGG1 variant was as-
sociated with increased the risk of ARC under the
heterogenous model (CG vs. CC: OR = 1.43, 95 % CI
= 1.04–1.96, P = 0.03) and dominant model (GG+CG
vs. CC: OR = 1.54, 95 % CI = 1.15–2.07, P = 0.004).
Figure 3 showed the relative strength of the associ-
ation between OGG1 rs1052133 and different types of
cataract under the heterogenous model.
Association between EPHA2 rs7543472 (C/T), rs11260867
(C/G) and ARC risk
Three articles contained 4902 cases and 3509 controls
evaluating the association of EPHA2 genetic polymor-
phisms and ARC occurrence. For rs7543472, our result
found that this variant was not associated with ARC risk
Fig. 1 Flow chart of selection process
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under any genetic models (T vs. C: OR = 1.13, 95 % CI =
0.92–1.38, P = 0.25; TT vs. CC: OR = 1.23, 95 % CI = 0.99–
1.52, P = 0.06; TC vs. CC: OR = 1.06, 95 % CI = 0.96–1.17,
P = 0.22; TT+TC vs. CC: OR = 1.08, 95 % CI = 0.99–1.19,
P = 0.10; TT vs. TC+CC: OR = 1.24, 95 % CI = 0.90–1.72,
P = 0.18). Subgroup analysis by phenotypes of cataract
showed a significant relationship between rs7543472 and
cortical cataract under the allele model (OR = 1.16, 95 %
CI = 1.01–1.33, P = 0.03), homogenous model (OR = 1.52,
95 % CI = 1.05–2.18, P = 0.03) and recessive model (OR =
1.54, 95 % CI = 1.18–2.01, P = 0.001) in the fixed-effect
model as shown in Fig. 4. No association was detected be-
tween rs7543472 and patients with nuclear cataract under
any genetic models.
For rs11260867, we did not observe a significant
positive correlation between this variant and ARC risk
under any genetic models as well (Table 3). Subgroup
analysis by phenotypes of cataract showed that this
variant was associated with increased the risk of cor-
tical cataract, not nuclear cataract under the
heterogenous model (CG vs. CC: OR = 0.66, 95 % CI =
0.43–1.00, P = 0.05) and dominant model (GG+CG vs.
CC: OR = 0.66, 95 % CI = 0.44–0.99, P = 0.04) as shown
in Fig. 5.
Sensitivity analysis and publication bias evaluation
To confirm whether each included study influences the
overall results or not, we successively omitted each sin-
gle study, respectively. Our result found that the pooled
ORs were not significantly changed. The funnel plots
were used to evaluate the publication bias. All the plots
were found to be roughly symmetrical, indicating no
publication bias presented as shown in Fig. 6.
Discussion
In this meta-analysis, we totally identified six articles
concerning three genetic polymorphisms. Our results
showed that CG genotype and GG+CG genotype of
OGG1 rs1052133 were associated with increased the risk
of ARC, in particular with cortical cataract. This signifi-
cant relationship was not found in EPHA2 polymor-
phisms (rs7543472 and rs11260867), however, subgroup
analysis by phenotypes of cataract showed that only in
cortical cataract, the genotypes of rs7543472 under the
allele model, homogenous model and recessive model;
genotypes of rs11260867 under the heterogenous model
and dominant model were associated with ARC risk.
This was the first meta-analysis concerning these three
SNPs in ARC risk.
Table 1 Main characteristics of included studies in this meta-analysis
First author Year Country Ethnicity Mean age Sample size Genotype
methodsARCs Controls ARCs Controls
Shiels A [29] 2008 USA European 75.7 ± 7.9 74.5 ± 7.6 213 104 PCR
Sundaresan P [30] 2012 India Asian – – 4198 3220 PCR
Zhang Y [31] 2012 China Asian 67.17 ± 6.92 65.77 ± 6.49 415 386 PCR-RFLP
Jiang SQ [32] 2013 China Asian 70.9 ± 8.2 60.2 ± 5.7 504 244 PCR
Celojevic D [33] 2014 Sweden European 72 ± 8.7 66 ± 6.9 491 185 PCR
Gharib AF [34] 2014 Egypt African 60.33 ± 6.22 67.83 ± 5.54 150 50 PCR
ARC age-related cataract, − not available, PCR-RFLP polymerase chain reaction-restriction fragment length polymorphism
Table 2 Genotype distribution of OGG1 and EPHA2 polymorphisms in cataract cases and controls
First author ARCs Controls HWE
rs1052133 CC CG GG C G CC CG GG C G
Zhang Y [31] 222 153 40 597 233 247 120 19 614 158 0.68
Jiang SQ [32] 72 222 210 366 642 40 103 101 183 305 0.29
Gharib AF [34] 77 51 22 205 95 32 16 2 80 20 1.00
rs7543472 TT TC CC T C TT TC CC T C
Shiels A [29] 146 53 5 345 63 58 41 3 157 47 0.40
Sundaresan P [30] 202 1419 2569 1823 6557 128 1054 2028 1310 5110 0.83
Celojevic D [33] 298 163 30 759 223 115 58 12 288 82 0.46
rs11260867 CC CG GG C G CC CG GG C G
Shiels A [29] 4 43 166 51 375 1 33 68 35 169 0.38
Sundaresan P [30] 25 623 3527 673 7677 24 448 2725 496 5898 0.50
Celojevic D [33] 317 158 16 792 190 121 58 6 300 70 0.96
ARC age-related cataract, HWE Hardy-Weinberg Equilibrium
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Cataract is the single largest contributor to blindness
in the world. Age is the major risk factor for cataract.
Even though several measures have been identified as a
solution for cataract treatment [35, 36], there is no obvi-
ous therapeutic benefits, and established medical treat-
ment for better prevention and treatment of cataract
was not built [37]. Moreover, this disease has a strong
genetic component. Therefore, understanding of genetic
polymorphisms within the lens may provide an insight
into the process of cataract onset.
OGG1 is involved in multiple vital processes. Recent
studies showed that OGG1 was highly expressed in the
Fig. 2 Meta-analysis of the relationship between the OGG1 rs1052133 and age-related cataract under the heterogenous model (a: CG vs. CC) and
dominant model (b: GG+CG vs. CC)
Table 3 Meta-analysis of OGG1 and EPHA2 polymorphisms in ARC based on different genetic models
Comparisons Total Cortical cataract Nuclear cataract PSC
OR (95 % CI) P OR (95 % CI) P OR (95 % CI) P OR (95 % CI) P
rs1052133
G vs. C 1.36 (0.99, 1.87) 0.05 1.50 (0.97, 2.32) 0.07 1.23 (0.98, 1.55) 0.07 1.26 (0.94, 1.68) 0.12
GG vs. CC 1.88 (0.96, 3.71) 0.07 2.18 (0.90, 5.28) 0.08 1.45 (0.87, 2.44) 0.16 1.61 (0.83, 3.09) 0.16
CG vs. CC 1.34 (1.06, 1.70) 0.01 1.43 (1.04, 1.96) 0.03 1.32 (0.93, 1.86) 0.12 1.22 (0.79, 1.88) 0.37
GG+CG vs. CC 1.45 (1.16, 1.81) 0.001 1.54 (1.15, 2.07) 0.004 1.37 (0.99, 1.90) 0.06 1.32 (0.88, 1.99) 0.18
GG vs. CG+CC 1.65 (0.82, 3.32) 0.16 1.83 (0.78, 4.29) 0.17 1.18 (0.79, 1.75) 0.43 1.30 (0.78, 2.17) 0.31
rs7543472
T vs. C 1.13 (0.92, 1.38) 0.25 1.16 (1.01, 1.33) 0.03 1.04 (0.75, 1.43) 0.83
TT vs. CC 1.23 (0.99, 1.52) 0.06 1.52 (1.05, 2.18) 0.03 1.08 (0.84, 1.39) 0.55
TC vs. CC 1.06 (0.96, 1.17) 0.22 0.99 (0.82, 1.20) 0.94 1.03 (0.92, 1.15) 0.61
TT+TC vs. CC 1.08 (0.99, 1.19) 0.10 1.06 (0.88, 1.27) 0.53 1.04 (0.93, 1.16) 0.49
TT vs. TC+CC 1.24 (0.90, 1.72) 0.18 1.54 (1.18, 2.01) 0.001 1.11 (0.72, 1.70) 0.63
rs11260867
G vs. C 0.99 (0.89, 1.11) 0.88 0.89 (0.73, 1.07) 0.20 1.09 (0.84, 1.40) 0.52
GG vs. CC 1.14 (0.71, 1.83) 0.59 0.62 (0.31, 1.24) 0.18 1.38 (0.76, 2.49) 0.29
CG vs. CC 1.08 (0.80, 1.47) 0.60 0.66 (0.43, 1.00) 0.05 1.46 (0.95, 2.23) 0.08
GG+CG vs. CC 1.08 (0.80, 1.45) 0.62 0.66 (0.44, 0.99) 0.04 1.43 (0.94, 2.18) 0.09
GG vs. CG+CC 1.16 (0.74, 1.81) 0.52 1.19 (0.55, 2.59) 0.66 0.95 (0.83, 1.10) 0.50
PSC posterior subcapsular cataract, OR odds ratio, 95 % CI 95 % confidence interval
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Fig. 3 Forest plot of the relative strength of the association between OGG1 rs1052133 and different types of cataract under the heterogenous
model (CG vs. CC)
Fig. 4 Meta-analysis of correlation of EPHA2 rs7543472 in cortical cataract under the allele model (a: T vs. C), homogenous model (b: TT vs. CC)
and recessive model (c: TT vs. TC+CC)
Zhang et al. BMC Ophthalmology  (2016) 16:168 Page 6 of 10
embryonic brain, and lack of OGG1 might cause severe
brain defects in brain integrity, balance and mobility
[38]. The acetylation of OGG1 was shown to play an im-
portant etiologic role in regulating its function in re-
sponse to DNA damage [39], and could be one of the
mechanisms for ARC development [40]. Xu et al. proved
that OGG1 might increase in lens epithelium cells with
ARC, and the alteration of OGG1 level was associated
with the location and opaque degrees of lens [41]. Wang
et al. proved that the reduced OGG1 expression was
correlated with hypermethylation of a CpG island of
OGG1 in lens cortex of ARC [42]. In addition, OGG1
mutations might delay the repair of oxidative DNA dam-
age, and be associated with increased disease risk [43].
Ali et al. showed that OGG1 mutation may prove to be
a good candidate of better diagnosis, treatment, and pre-
vention of breast cancer [44]. Zhang et al. suggested that
OGG1 Ser326Cys polymorphism might be associated
with increased risk of ARC [31]. While Su et al. did not
find a correlation between OGG1 variants and ARC risk
in Han Chinese from the Jiangsu Eye Study [45].
EPHA2 is an epithelial cell tyrosine kinase, and was
shown to be enriched in adult tissues [46]. It is highly
expressed in aggressive human cancers. During tumor
progression, EPHA2 receptor can gain ligand-
independent pro-oncogenic functions due to Akt activa-
tion and reduced ephrin-A ligand engagement [47].
Moreover, EPHA2 can function as a therapeutic target
for antibody therapy of cancers and diseases [48, 49].
Dunne et al. found that EPHA2 was a key driver of inva-
sion and migration and a synthetically lethal target in
KRASMT colorectal cancer, indicating that EPHA2 was
a poor prognostic marker [50]. Kato et al. showed a
promising role for EPHA2 as a target for antibody treat-
ment in melanoma and enhanced the therapeutic effect
as an agonistic antibody to EPHA2 [51]. Genetic and
pharmacological inhibition of EPHA2 induces apoptosis
and abrogates tumorigenic growth of tumor cells [52].
Recent studies have identified EPHA2 as a surprisingly
abundant plasma membrane component in cells of the
ocular lens [53]. Mutations in EPHA2 have been shown
to underlie inherited forms of cataract in humans [54,
55]. Common variants in EPHA2 have been associated
with the much more prevalent age-related form of cata-
ract. Dave et al. showed that mutations in EPHA2
accounted for 4.7 % of inherited cataract cases in South-
Eastern Australia, and a rare variant rs139787163 was
potentially associated with increased susceptibility to
cataract, providing a link between congenital and age-
related cataract [56]. Furthermore, the cytoprotective
and antiapoptotic function of EPHA2 in lens epithelial
cells was abolished by the functional polymorphisms
[52]. These results indicated the potential role of EPHA2
in maintaining lens clarity during aging by promoting
cell viability.
Several limitations were presented in this meta-
analysis. First of all, the number of included studies
for each SNP was small, future large-scale researches
with more ethnicities are needed to further evaluate
the relationship. Secondly, between-study heterogen-
eity was presented in several comparisons. Thirdly,
we did not conduct the subgroup analysis by ethnici-
ties due to the less data, which should be concerned
in the future. Lastly, gene-gene and gene-
environment interactions were not addressed in our
meta-analysis.
Fig. 5 Forest plot of the association between EPHA2 rs11260867 and cortical cataract risk under the heterogenous model (a: CG vs. CC) and
dominant model (b: GG+CG vs. CC)
Zhang et al. BMC Ophthalmology  (2016) 16:168 Page 7 of 10
Conclusions
Our results indicated that CG genotype and GG+CG
genotype of OGG1 rs1052133 might be risk factor for
ARC, especially in cortical cataract risk. The T allele and
TT genotype of EPHA2 rs7543472; CG genotype and
GG+CG genotype of EPHA2 rs11260867 were associ-
ated with cortical cataract risk. Future studies are still
required to re-evaluate the results of OGG1 and EPHA2
polymorphisms in ARC risk.
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